TEVA PHARMACEUTICAL INDUSTRIES LTD
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.
Why Teva Pharmaceutical Stock Surged This Week
Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.
Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2026 Q2 earnings call.
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...
Teva Pharmaceutical Industries Ltd (TEVA) reports robust performance in innovative products, raising revenue guidance despite challenges in the generics segment.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsChristopher Stevo - Senior Vice President...
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents a share.
Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported mixed second-quarter results, with revenue exceeding Wall Street expectations while adjusted earnings fell short due to acquisition-related costs.
Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Congressional Trades in $TEVA
View full $TEVA trading history →Insider Trades (Form 4)
MIGNONE ROBERTO
Savage Brian
Satchi-Fainaro Ronit
Weiss Amir
Lippman Evan
Zaks Tal Zvi
Jover Placid
Hughes Eric A
Key People
MIGNONE ROBERTO
Director
Zaks Tal Zvi
Director
Shields Matthew
EVP, Global Operations
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
LIEBERMAN GERALD M
Director
Satchi-Fainaro Ronit
Director
Crane Rosemary A
Director
Elstein Amir
Director
Lichtenstein Chen
Director
Political Giving
$20,000 given to 7 candidates across 11 disclosed contributions (FEC Schedule A).
John Curtis
Scott H. Peters
Ashley Moody
Jake Auchincloss
August Lee Pfluger
Lori Trahan
Debbie Dingell
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro